Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.”

Detalles Bibliográficos
Autores principales: Picardi, Marco, Giordano, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018111/
https://www.ncbi.nlm.nih.gov/pubmed/33792226
http://dx.doi.org/10.3324/haematol.2020.278203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018111/
https://www.ncbi.nlm.nih.gov/pubmed/33792226
http://dx.doi.org/10.3324/haematol.2020.278203

Ejemplares similares